Is CI a good stock to buy?
Cigna Corporation · end-of-day data as of Nov 13, 2026
- PT$342.07 +15.2%
- ConsensusBuy · 25
- P/E vs sector-59.3%
- FCF yield+10.6%
- MAs3 of 4
- Sector▲ +15.9%
- Earnings in83d
- P/E13.1x
- RSI51
- Support-0.9%
- Resistance+2.5%
- Off 52w high-6.6%
- Volume0.9x
- Bollingerlower half
- News0.00
- Trendsideways
- 52w range$258–$318
- ATR+2.8%
- Off ATH-19.9%
- P/E vs own+11.2%
- Insiders-$924K
- MACD-1.12
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Cigna a good stock to buy?
Cigna is strong on 3 of the 5 questions about the business; weak on economics. The price is low: 13.1 times its earnings, below its 3-year median of 17.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage some edge
- Economics thin margins
- Execution delivers
- Fragility sturdy
- Price below its usual
CI sales growth revenue growth
+15%a year, for the last 3 yearsCigna's sales grew 15% a year for 3 years, to $275B in fiscal 2025.
CI analysts' forecast revenue estimates
+5%the sales they expect next fiscal year, on the lastAnalysts expect Cigna's sales to grow 5% to $288B in fiscal 2026 (11 analysts).
CI competitors
pretickt analysis+7%its sales in 12 months, on a year before
Cigna's sales grew 7% in the 12 months to Sep 30, 2026, faster than CVS Health (+7%), Centene (+5%) and Elevance Health (+4%), slower than Humana (+22%).
CI sales by business revenue by segment
83%of its sales from EvernorthEvernorth brought Cigna 83% of its sales in fiscal 2025; Cigna Healthcare 17%.
CI return on capital ROIC
pretickt analysis14%earned before tax on the money invested in itCigna earned 14% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Elevance Health 11%, CVS Health 10%, Humana 8% and Centene 7%.
CI margin on each sale gross margin
9%left after making the productCigna kept 9% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 15%.
CI margin after costs profit margin
3%of sales left after running the businessCigna's operating margin was 3% in the 12 months to Sep 30, 2026, against 5% in fiscal 2022.
CI cash generated free cash flow
$8.27Bcash left after investing, last 12 monthsCigna generated $8.27B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
CI earnings vs estimates
7 of 8quarters above the analysts' estimateCigna beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Nov 5, 2026.
CI insider selling
-$66.84Msold, net, by its executives in 12 monthsCigna's executives and directors sold a net $66.84M of shares in the 12 months to Nov 13, 2026; none bought.
CI number of employees
-8%fewer people in a yearCigna had 67,700 employees at the end of fiscal 2025, 8% fewer than a year before.
CI CEO pay
$22.87Mfor fiscal 2025, 76% of it in stock and optionsCigna paid its CEO $22.87M for fiscal 2025, 76% of it in stock and options.
CI financial health Altman Z-score
2.8Altman Z-score, safe above 3Cigna's Altman Z-score is 2.8 (Nov 13, 2026), between 1.8 and 3, the grey zone.
CI quality checks Piotroski score
7 of 9checks passedCigna passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets and gross margin.
CI biggest customers
19%of sales from its biggest customerOne customer, unnamed in Cigna's 10-K, made 19% of its sales in fiscal 2025.
CI in past recessions
pretickt analysis-4%its sales in the worst oneCigna's sales fell in 1 of the last 2 US recessions, by as much as 4% in fiscal 2009.
CI price vs profit P/E ratio
13.1×a year's earningsCigna's P/E ratio is 13.1 (Nov 13, 2026), below its 3-year median of 17.6.
CI price vs competitors
pretickt analysis13.1×a year's earnings, against its competitorsInvestors pay 13.1 times Cigna's earnings (Nov 13, 2026), more than for CVS Health (10.4), less than for Humana (43.8), Centene (24.4) and Elevance Health (18.3).
CI analysts' target price target
+15%to their average targetAnalysts' average price target for Cigna is $342, 15% above the Nov 13, 2026 close of $297.00.
CI growth priced in fair value
pretickt analysis-3%a year, for ten years, and still worth the priceAt $297.00 a share, Cigna's free cash flow could shrink about 3% a year for ten years and still be worth the price (Nov 13, 2026).
What is Cigna's P/E ratio?
Cigna's P/E ratio is 13.1 (Nov 13, 2026), below its 3-year median of 17.6. Investors pay 13.1 times Cigna's earnings (Nov 13, 2026), more than for CVS Health (10.4), less than for Humana (43.8), Centene (24.4) and Elevance Health (18.3).
Who are Cigna's biggest competitors?
pretickt compares Cigna with Elevance Health, Humana, CVS Health and Centene. Cigna's sales grew 7% in the 12 months to Sep 30, 2026, faster than CVS Health (+7%), Centene (+5%) and Elevance Health (+4%), slower than Humana (+22%).
Is Cigna profitable?
Cigna's operating margin was 3% in the 12 months to Sep 30, 2026, against 5% in fiscal 2022. Cigna generated $8.27B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
Are insiders selling Cigna stock?
Cigna's executives and directors sold a net $66.84M of shares in the 12 months to Nov 13, 2026; none bought.
How does Cigna make money?
Evernorth brought Cigna 83% of its sales in fiscal 2025; Cigna Healthcare 17%.
Who owns Cigna stock?
1,776 institutions hold 91% of Cigna's shares (Jun 30, 2026); Vanguard, BlackRock and State Street added shares that quarter.
How many employees does Cigna have?
Cigna had 67,700 employees at the end of fiscal 2025, 8% fewer than a year before.
Who are Cigna's biggest customers?
One customer, unnamed in Cigna's 10-K, made 19% of its sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.